Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lorusso

Showing results (211-220 of 280) with videos related to

Pageof 28
Sort By:
Cancer Chemotherapy and Pharmacology|January 25, 2012
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancerSandhya Girish, Manish Gupta, Bei Wang, et al.
Journal of Pharmaceutical Sciences|April 24, 2013
Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumorsDaniele Ouellet, Kenneth F Grossmann, Giselle Limentani, et al.
Journal for Immunotherapy of Cancer|March 15, 2022
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I studyAung Naing, John D Powderly, John J Nemunaitis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2005
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignanciesPatricia M Lorusso, Alex A Adjei, Mary Varterasian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2010
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2Joseph Paul Eder, Geoffrey I Shapiro, Leonard J Appleman, et al.
Psychopharmacology|August 14, 2023
Sprague Dawley rats from different vendors vary in the modulation of prepulse inhibition of startle (PPI) by dopamine, acetylcholine, and glutamate drugsS B Caine, S Plant, K Furbish, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2014
A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014Wells A Messersmith, Geoffrey I Shapiro, James M Cleary, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2012
Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumorsPatricia M Lorusso, Martin J Edelman, Susan L Bever, et al.
Cancer|March 11, 2026
Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trialDeborah B Doroshow, Geoffrey I Shapiro, Khanh Do, et al.
The New England Journal of Medicine|September 4, 2009
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449Charles M Rudin, Christine L Hann, John Laterra, et al.
Pageof 28

Showing results (211-220 of 280) with videos related to

Sort By:
Pageof 28
Cancer Chemotherapy and Pharmacology|January 25, 2012
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancerSandhya Girish, Manish Gupta, Bei Wang, et al.
Journal of Pharmaceutical Sciences|April 24, 2013
Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumorsDaniele Ouellet, Kenneth F Grossmann, Giselle Limentani, et al.
Journal for Immunotherapy of Cancer|March 15, 2022
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I studyAung Naing, John D Powderly, John J Nemunaitis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2005
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignanciesPatricia M Lorusso, Alex A Adjei, Mary Varterasian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2010
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2Joseph Paul Eder, Geoffrey I Shapiro, Leonard J Appleman, et al.
Psychopharmacology|August 14, 2023
Sprague Dawley rats from different vendors vary in the modulation of prepulse inhibition of startle (PPI) by dopamine, acetylcholine, and glutamate drugsS B Caine, S Plant, K Furbish, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2014
A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014Wells A Messersmith, Geoffrey I Shapiro, James M Cleary, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2012
Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumorsPatricia M Lorusso, Martin J Edelman, Susan L Bever, et al.
Cancer|March 11, 2026
Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trialDeborah B Doroshow, Geoffrey I Shapiro, Khanh Do, et al.
The New England Journal of Medicine|September 4, 2009
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449Charles M Rudin, Christine L Hann, John Laterra, et al.
Pageof 28